The use of mycophenolate mofetil in liver transplant recipients

Detry, Olivier; De Roover, Arnaud; Delwaide, Jean; Meurisse, Michel; Honore, Pierre

doi:10.1517/14656566.4.11.1949

No full text

Article (Scientific journals)

The use of mycophenolate mofetil in liver transplant recipients

Detry, Olivier; De Roover, Arnaud; Delwaide, Jean et al.

2003 • In Expert Opinion on Pharmacotherapy, 4 (11), p. 1949-1957

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/1142

DOI
10.1517/14656566.4.11.1949

PubMed
14596648

Files (3)Send to Details Statistics Bibliography Similar publications

Files

Full Text

No document available.

Full Text Parts

ExpOpinion.2003.pdf

Publisher postprint (29.17 MB)

Request a copy

Proof.pdf

Author postprint (411.27 kB)

Request a copy

Exp.opinion.2003.pdf

Author preprint (232.04 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

adult; children; immunosuppression; kidney; liver transplantation; mycophenolate mofetil; nephrotoxicity; fescue therapy; review; side effects; solid organ; surgery; therapy; transplantation

Abstract :

[en] Mycophenolate mofetil is an important drug in the modern immunosuppressive arsenal. Mycophenolate mofetil is the semisynthetic morpholinoethyl ester of mycophenolate acid. Mycophenolate acid prevents T and B cell proliferation by specifically inhibiting a purine pathway required for lymphocyte division. This paper extensively reviews the experience of mycophenolate mofetil use in liver transplant recipients. In randomised trials, mycophenolate mofetil decreased the rate of acute rejection after liver transplantation, without a significant increase of septic complications. However, so far, there are no data indicating that mycophenolate mofetil increases liver transplant patient or graft survivals. Mycophenolate mofetil is interesting because of its particular side effects profile, which is very different from the other immunosuppressants. The absence of mycophenolate mofetil nephrotoxicity is of specific interest in liver recipients with impairment of renal function. The monitoring of mycophenolate acid area under the concentration time curve might be interesting to limit side effects and provide better clinical efficacy but the exact role of mycophenolate acid monitoring in liver recipients has yet to be further evaluated in large series.

Disciplines :

Surgery
Anesthesia & intensive care
Immunology & infectious disease
Pharmacy, pharmacology & toxicology
Gastroenterology & hepatology

Author, co-author :

Detry, Olivier ; Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation

De Roover, Arnaud ; Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation

Delwaide, Jean ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie

Meurisse, Michel ; Université de Liège - ULiège > Département des sciences cliniques > Chirurgicale abdominale

Honore, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation

Language :

English

Title :

The use of mycophenolate mofetil in liver transplant recipients

Publication date :

November 2003

Journal title :

Expert Opinion on Pharmacotherapy

ISSN :

1465-6566

eISSN :

1744-7666

Publisher :

Ashley Publications Ltd, London, United Kingdom

Volume :

Issue :

Pages :

1949-1957

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 25 November 2008

Statistics

Number of views

164 (12 by ULiège)

Number of downloads

174 (7 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

HELDERMAN JH, BENNETT WM, CIBRIK DM, KAUFMAN DB, KLEIN A, TAKEMOTO SK: Immunosuppression: practice and trends. Am. J. Transpl. (2003) 3:41-52.
GOSIO B: Ricerche batteriologiche e chimiche sulle alterazion delmais; contributo alletiologica della pellagra. Ig. Sanita Pubblica Ann. (1896) 7:825.
SUZUKI S, KIMURA T, ANKO K: Anitumoral activity of mycophenolic acid. J. Antibiot. (1969) 22:297-302.
WILLIAMS RH, LIVELY DH, DELONG DC: Mycophenolic acid: antiviral and antitumor properties. J. Antibiot. (1968) 21:463-464.
CARTER SB, FRANKLIN TJ, JONES DF, LEONARD BJ, MILLS SD, TURNER WB: Mycophenolic acid: an anti-cancer compound with unusual properties. Nature (1969) 223:848.
BREWIN TB, COLE MP, JONES CT: Mycophenolic acid (NSC-129185): preliminary clinical trials. Cancer Chemother. Rep. (1972) 56:83-87.
FLOREY HW, GILLIVER K, JENNINGS MA: Mycophenolic acid: an antibiotic from Penicillium brevicopactum. Lancet (1946) 1:46-49.
MELE TS, HALLORAN PF: The use of mycophenolate mofetil in transplant recipients. Immunopharmacolog (2000) 47:215-245.
SWEENEY MJ, HOFFMAN DH, ESTERMAN MA: Metabolism and biochemistry of mycophenolic acid. Cancer Res. (1972) 32:1803-1809.
LINTRUP J, HYLTOFT-PETERSEN P, KNUDTZON S: Metabolic studies in man with mycophenolic acid (NSC-129185), a new antitumor agent. Cancer Chemother. Rep. (1972) 56:229-235.
HALE MD, NICHOLLS AJ, BULLINGHAM RE et al.: The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin. Pharmacol. Ther. (1998) 64:672-683.
LEE WA, GU L, MIKSZTAL AR, CHU N, LEUNG K, NELSON PH: Bioavailability improvement of mycophenolic acid through amino ester derivitization. Pharmacol. Res. (1990) 7:161-166.
PESCOVITZ MD, CONTI D, DUNN J et al.: Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. Clin. Transplant. (2000) 14:179-188.
SHAW LM, KORECKA M, VENKATARAMANAN R, GOLDBERG L, BLOOM R, BRAYMAN KL: Mycophenolic acid pharmacodynamics and pharmocokinetics provide a basis for rational monitoring strategies. Am. J. Tanspl. (2003) 3:534-542.
OELLERICH M, SHIPKOVA M, SCHUTZ E et al.: Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther. Drug Monit. (2000) 22:20-26.
WEBER IT, SHIPKOVA M, ARMSTRONG VW et al.: The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. J. Am. Soc. Nephrol. (2002) 13:759-768.
JAIN A, VENKATARAMANAN R, HAMAD IS et al.: Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J. Clin. Pharmacol. (2001) 41:268-276.
AW MM, BROWN NW, ITSUKA T et al.: Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. Liver Transpl. (2003) 9:383-388.
GRASSER B, IBERER F, SCHAFFELLNER S et al.: Trough level-guided mycophenolate mofetil rejection prophylaxis in liver transplantation. Transplant. Proc. (2001) 33:2154-2156.
VAN GELDER T, KLUPP J, BARTEN MJ, CHRISTIANS U, MORRIS RE: Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther. Drug Monit. (2001) 23:119-228.
SMAK GREGOOR PJ, VAN GELDER T, HESSE CJ, VAN DER MAST BJ, VAN BESOUW NM, WEIMAR W: Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol. Dial. Transplant. (1999) 14:706-708.
NOWAK I, SHAW LM: Mycophenolate acid binding to human serum albumin: characterisation and relation to pharmacodynamics. Clin. Chem. (1995) 41:1011-1017.
KAPLAN B, MEIER-KRIESCHE HU, FRIEDMAN G et al.: The effect of renal insufficiency on mycophenolic acid protein binding. J. Clin. Pharmacol. (1999) 39:715-720.
MEIER-KRIESCHE HU, SHAW LM, KORECKA M, KAPLAN B: Pharmacokinetics of mycophenolic acid in renal insufficiency. Ther. Drug Monit. (2000) 22:27-30.
JAIN AB, HAMAD I, ZUCKERMAN S et al.: Effect of t-rube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. Liver Transpl. Surg. (1999) 5:101-106.
SCHMIDT LE, RASMUSSEN A, NORRELYKKE MR, POULSEN HE, HANSEN BA: The effect of selective bowel decontamination on the pharmacokinetics of mycophenolate mofetil in liver transplant recipients. Liver Transpl. (2001) 7:739-742.
PLATZ KP, BECHSTEIN WO, ECKHOFF DE, SUZUKI Y, SOLLINGER HW: RS-61443 reverses acute allograft rejection in dogs. Surgery (1991) 110:736-740.
PLATZ KP, SOLLINGER HW, HULLETT DA, ECKHOFF DE, EUGUI EM, ALLISON AC: RS-61443-a new, potent immunosuppressive agent. Transplantation (1991) 51:27-31.
EUROPEAN MYCOPHENOLATE MOFETIL COOPERATIVE STUDY GROUP: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet (1995) 345:1321-1325.
THE TRICONTINENTAL MYCOPHENOLATE MOFETIL RENAL TRANSPLANTATION STUDY GROUP: A blinded, randomised clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation (1996) 61:1029-1037.
SOLLINGER HW: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation (1995) 60:225-232.
JAIN A, KASHYAP R, DODSON F et al.: A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report. Transplantation (2001) 72:1091-1097.
STERNECK M, FISCHER L, GAHLEMANN C, GUNDLACH M, ROGIERS X, BROELSCH C: Mycophenolate mofetil for prevention of liver allograft rejection: initial results of a controlled clinical trial. Ann. Tansplant. (2000) 5:43-46.
WIESNER R, RABKIN J, KLINTMALM G et al.: A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl. (2001) 7:442-450.
HEBERT MF, ASCHER NL, LAKE JR et al.: Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients. Transplantation (1999) 67:707-712.
PLATZ KP, MUELLER AR, NEUHAUS R, KECK HH, LOBECK H, NEUHAUS P: FK 506 and mycofenolate mofetil rescue for acute steroid-resistant and chronic rejection after liver transplantation. Transplant. Proc. (1997), 29:2872-2874.
PFITZMANN R, KLUPP J, LANGREHR JM et al.: Mycophenolate mofetil for treatment of ongoing or chronic rejections after liver transplantation. Transplant. Proc. (2002) 34:2938-2939.
PFITZMANN R, KLUPP J, LANGREHR JM et al.: Mycophenolate mofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. Transplantation (2003) 76:130-136.
DALY I, JAIN A, REYES J, FUNG J: Mycophenolate mofetil for treatment of chronic rejection in liver allograft under tacrolimus. Transplant. Proc. (2002) 34:1503.
GAVLIK A, GOLDBERG MG, TSAROUCHA A et al.: Mycophenolate mofetil rescue therapy in liver transplant recipients. Transplant. Proc. (1997) 29:549-552.
GAVLIK A, DEMIRBAS A, TSAROUCHA A et al.: Mycophenolate mofetil rescue therapy in liver transplant recipients: an extended follow-up. Tranplant. Proc. (1997) 29:2971-2972.
KATO T, RUIZ P, DEFARIA W et al.: Mycophenolate mofetil rescue therapy in patients with chronic hepatic allograft rejection. Tanplant. Proc. (1999) 31:396.
RINGE B, BRAUN F, SCHUTZ E et al: A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. Transplantation (2001) 71:508-515,
WASHBURN K, SPEEG KV, ESTERL R et al.: Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. Transplantation (2001) 72:1675-1679.
FIGUERAS J, BERNARDOS A, PRIETO M et al.: Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients. Transplant. Proc. (2002) 34:1511-1513.
STEGALL MD, WACHS ME, EVERSON G et al: Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Transplantation, (1997) 64:1755-1760.
PERSSON H, NORDEN G, KARLBERG I, FRIMAN S: Glomerular filtration rate after liver transplantation with a low-dose cyclosporin protocol. Tanspl. Int. (1994) 7:172-176.
BARKMANN A, NASHAN B, SCHMIDT HH et al.: Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil. Transplantation (2000) 69:1886-1890.
PFITZMANN R, KLUPP J, LANGREHR JM et al.: Mycophenolate mofetil reduces calcineurin inhibitor-induced side effects after liver transplantation. Transplant. Proc. (2002) 34:2936-2937.
HODGE EE, REICH DJ, CLAVIEN PA, KIM-SCHLUGER L: Use of mycophenolate mofetil in liver transplant recipients experiencing renal dysfunction on cyclosporine or tacrolimus-randomized, prospective, multicenter study results. Transplant. Proc. (2002) 34:1546-1547.
TORRAS J, FIGUERAS J, LAMA C et al.: Mycophenolate mofetil overlap in liver transplant recipients with chronic cyclosporine nephrotoxicity. Transplant. Proc. (1999) 31:2430.
RAIMONDO ML, DAGHER L, PAPATHEODORIDIS GV et al.: Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation (2003) 75:186-190.
CANTAROVICH M, TZIMAS GN, BARKUN J, DESCHENES M, ALPERT E, TCHERVENKOV J: Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction. Transplantation (2003) 76:98-102.
PAPATHEODORIDIS GV, O'BEIRNE J, MISTRY P, DAVIDSON B, ROLLES K, BURROUGHS AK: Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment: a preliminary report. Transplantation (1999) 68:155-157.
HERRERO JI, QUIROGA J, SANGRO B et al.: Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Liver Transpl. Surg. (1999) 5:414-420.
DETRY O, DE ROOVER A, HONORE P, DELWAIDE J, JACQUET N, MEURISSE M: Mycophenolate mofetil monotherapy in stable liver transplant recipients with progressive renal failure. Transplant. Proc. (2002) 34:782-783.
SCHLITT HJ, BARKMANN A, BOKER KH et al.: Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet (2001) 357:587-591.
STEWART SF, HUDSON M, TALBOT D, MANAS D, DAY CP: Mycophenolate mofetil monotherapy in liver transplantation. Lancet (2001) 357:609-610.
ROMERO F, RODRIGUEZ-ITURBE B, PARRA G, GONZALEZ L, HERRERA-ACOSTA J, TAPIA E: Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int. (1999) 55:945-955.
BIRKELAND SA, ANDERSEN HK, HAMILTON-DUTOIT SJ: Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol. Transplantation (1999) 67:1209-1214.
GONG ZJ, DE MEYER S, CLARYSSE C et al.: Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. J. Viral Hepat. (1999) 6:229-236.
NEYTS J, ANDREI G, DE CLERCQ E: The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob. Agents Chemotber. (1998) 42:216-222.
HOSSAIN MM, COULL JJ, DRUSANO GL, MARGOLIS DM: Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antiviral Res. (2002) 55:41-52.
BEN-ARI Z, ZEMEL R, TUR-KASPA R: The addition of mycophenolate mofetil for suppressing hepatitis B virus replication in liver recipients who developed lamivudine resistance-no beneficial effect. Transplantation (2001) 71:154-156.
FASOLA CG, NETTO GJ, JENNINGS LW et al.: Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil. Transplant. Proc. (2002) 34:1563-1564.
BAHRA M, NEUMANN UP, HARREN M et al.: Significance of mycophenolate mofetil treatment in patients with HCV reinfection after liver transplantation: impact on clinical course and histologic damage. Transplant. Proc. (2002) 34:2934-2935.
PLATZ KP, MUELLER AR, WILLIMSKI C et al.: Indication for mycophenolate mofetil therapy in hepatitis C patients undergoing liver transplantation. Transplant. Proc. (1998) 30:2232-2233.
JAIN A, KASHYAP R, DEMETRIS AJ, EGHSTESAD B, POKHARNA R, FUNG JJ: A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Tanspl. (2002) 8:40-46.
BUNCHMAN T, NAVARRO M, BROYER M et al.: The use of mycophenolate mofetil suspension in pediatric renal allograft recipients. Pediatr. Nephrol. (2001) 16:978-984.
BROWN NW, AW MM, MIELI-VERGANI G, DHAWAN A, TREDGER JM: Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effects of cyclosporine and tacrolimus comedication. Ther. Drug Monit. (2002) 24:598-606.
CHARDOT C, NICOLUZZI JE, JANSSEN M et al.: Use of mycophenolate mofetil as rescue therapy after pediatric liver transplantation. Transplantation (2001) 71:224-229.
AW MM, SAMAROO B, BAKER AJ et al.: Calcineurin-inhibitor related nephrotoxicity- reversibility in paediatric liver transplant recipients. Transplantation (2001) 72:746-749.
PATERSON DL, SINGH N, PANEBIANCO A et al.: Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil. Transplantation (1998) 66:593-598.
SEIKALY MG: Mycophenolate mofetil -is it worth the cost? The in-favor opinion. Pediatr. Transplant. (1999) 3:79-82.
SULLIVAN SD, GARRISON LP, BEST JH: The cost effectiveness of mycophenolate mofetil in the first year after primary cadaveric transplant. US Renal Transplant Mycophenolate Mofetil Study Group. J. Am. Soc. Nephrol. (1997) 8:1592-1598.